tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Dr. Reddy’s Laboratories Receives Positive USFDA Inspection Outcome

Story Highlights
  • Dr. Reddy’s received USFDA’s EIR for its Telangana facility on August 7, 2025.
  • The inspection was classified as ‘Voluntary Action Indicated’, closing the inspection officially.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Dr. Reddy’s Laboratories Receives Positive USFDA Inspection Outcome

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

The latest announcement is out from Dr Reddy’s Laboratories ( (RDY) ).

On August 7, 2025, Dr. Reddy’s Laboratories received an Establishment Inspection Report (EIR) from the United States Food & Drug Administration (USFDA) for its API manufacturing facility in Miryalaguda, Telangana, India. The inspection, which was initially conducted in May 2025, was classified as ‘Voluntary Action Indicated (VAI)’, indicating that the inspection is officially closed. This outcome suggests that while there were some issues noted, they are not significant enough to warrant further regulatory action, which is a positive development for the company’s compliance status and operational stability.

The most recent analyst rating on (RDY) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.

Spark’s Take on RDY Stock

According to Spark, TipRanks’ AI Analyst, RDY is a Neutral.

Dr Reddy’s Laboratories exhibits strong financial fundamentals with consistent revenue and profit growth. However, bearish technical indicators and balanced earnings call sentiment due to challenges in the U.S. market and increased expenses weigh down the overall score. The valuation is reasonable, providing moderate income potential.

To see Spark’s full report on RDY stock, click here.

More about Dr Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited is a pharmaceutical company based in Hyderabad, India. The company is involved in the manufacturing and marketing of a wide range of pharmaceutical products, including active pharmaceutical ingredients (APIs) and generic medications. Dr. Reddy’s focuses on providing affordable and innovative medicines to patients globally, with a significant presence in the Indian and international markets.

Average Trading Volume: 1,573,944

Technical Sentiment Signal: Hold

Current Market Cap: $11.55B

For detailed information about RDY stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1